Literature DB >> 10493983

Evaluation of cases with silicosis using the parameters related to Fas-mediated apoptosis.

T Otsuki1, K Ichihara, A Tomokuni, H Sakaguchi, T Aikoh, T Matsuki, Y Isozaki, F Hyodoh, M Kusaka, S Kita, A Ueki.   

Abstract

To establish a new clinical index for immunological abnormalities occurring in silicosis, several clinical parameters related to Fas-mediated apoptosis; i.e., membrane Fas expression on peripheral blood lymphocytes (mFas), serum soluble Fas levels (sFas), serum soluble Fas ligand levels (sFasL), and soluble/membrane Fas mRNA expression ratios (s/mFas ExR) in peripheral blood mononuclear cells (PBMC) were investigated. Fifty-eight silicosis patients with no clinical symptoms of autoimmune diseases were the subjects of this study. Factor analysis was performed using 12 clinical parameters including four parameters related to Fas-mediated apoptosis. Two common factors were identified. Factor 1 which consisted of the following parameters; duration of exposure, symptomatic dyspnea, PO2, PCO2, and A-aDO2, should be designated as the respiratory factor for cases with silicosis. The parameters of factor 2 were serum IgG, sFas with high factor loading, titer of ANA, sFasL, and s/mFas ExR. These parameters of factor 2 are indicative of the immunological disorders occurring in silicosis cases. Some cases exhibited abnormalities in parameters of factor 2 but not factor 1. The factor analysis clearly demonstrated that the parameters related to Fas-mediated apoptosis should be the most beneficial for predicting the pre-clinical status of complicated autoimmune diseases in silicosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493983     DOI: 10.3892/ijmm.4.4.407

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  4 in total

1.  Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.

Authors:  Shuko Murakami; Yasumitsu Nishimura; Megumi Maeda; Naoko Kumagai; Hiroaki Hayashi; Ying Chen; Masayasu Kusaka; Takumi Kishimoto; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2009-03-18       Impact factor: 3.674

2.  Detection of anti-topoisomerase I autoantibody in patients with silicosis.

Authors:  Akiko Tomokuni; Takemi Otsuki; Haruko Sakaguchi; Yumika Isozaki; Fuminori Hyodoh; Masayasu Kusaka; Ayako Ueki
Journal:  Environ Health Prev Med       Date:  2002-04       Impact factor: 3.674

Review 3.  Silica exposure and altered regulation of autoimmunity.

Authors:  Suni Lee; Hidenori Matsuzaki; Naoko Kumagai-Takei; Kei Yoshitome; Megumi Maeda; Ying Chen; Masayasu Kusaka; Kozo Urakami; Hiroaki Hayashi; Wataru Fujimoto; Yasumitsu Nishimura; Takemi Otsuki
Journal:  Environ Health Prev Med       Date:  2014-08-19       Impact factor: 3.674

4.  Clinical evaluation of CENP-B and Scl-70 autoantibodies in silicosis patients.

Authors:  Suni Lee; Hiroaki Hayashi; Naoko Kumagai-Takei; Hidenori Matsuzaki; Kei Yoshitome; Yasumitsu Nishimura; Kozo Uragami; Masayasu Kusaka; Shoko Yamamoto; Miho Ikeda; Tamayo Hatayama; Wataru Fujimoto; Takemi Otsuki
Journal:  Exp Ther Med       Date:  2017-04-12       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.